UBE2I and metabolic dysfunction-associated steatotic liver disease: Although Ubc9‐mediated SUMOylation are recognized to regulate the multiple aspects of hepatic biological processes, its impact on hepatic senescence and metabolic dysfunction‐associated steatotic liver disease (MASLD), however, is yet to be fully addressed.